Aratana Therapeutics (PETX) Misses Q1 EPS by 10c

Aratana Therapeutics (NASDAQ: PETX) reported Q1 EPS of ($0.52), $0.10 worse than the analyst estimate of ($0.42). Revenue for the quarter came in at $172 thousand versus the consensus estimate of $140 thousand.

For earnings history and earnings-related data on Aratana Therapeutics (PETX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Tvardi Therapeutics (TVRD) Tops Q2 EPS by 1c
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c